tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

JPMorgan ups BridgeBio target, adds ‘Positive Catalyst Watch’

JPMorgan analyst Anupam Rama raised the firm’s price target on BridgeBio (BBIO) to $70 from $55 and keeps an Overweight rating on the shares. The firm also added BridgeBio to its “Positive Catalyst Watch List” ahead of pipeline readouts over the next six months. JPMorgan has a positive outlook on the company’s near-term readouts citing “prior de-risking data.” If the company’s three readouts are positive, the firm sees the stock reaching $80-$100. Conversely, if all three miss, the base value of Attruby alone is in the mid-$30s to low-$40s per share range, which creates a favorable risk/reward, JPMorgan contends.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1